Excalibur Fund Managers
25
13M
17
1.00
9
0.32
11
- Stages of investment
- Areas of investment
Summary
Excalibur Fund Managers appeared to be the VC, which was created in 1996. The leading representative office of defined VC is situated in the London. The venture was found in Europe in United Kingdom.
The fund has exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most successful fund investment fields, there are Biotechnology, Medical. Among the various public portfolio startups of the fund, we may underline BioVex, Neurotech, Ardana Bioscience
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Excalibur Fund Managers, startups are often financed by Techno Venture Management, Scottish Equity Partners, Avlar BioVentures. The meaningful sponsors for the fund in investment in the same round are 3i Group, Avlar BioVentures, Alice Ventures. In the next rounds fund is usually obtained by Scottish Equity Partners, GeneChem Inc., Avlar BioVentures.
The real fund results show that this VC is 24 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2003. Comparing to the other companies, this Excalibur Fund Managers performs on 15 percentage points more the average number of lead investments. The increased amount of exits for fund were in 2005.
Besides them, we counted 3 critical employees of this fund in our database.
Investments analytics
Analytics
- Total investments
- 25
- Lead investments
- 9
- Exits
- 11
- Rounds per year
- 1.00
- Follow on index
- 0.32
- Investments by industry
- Biotechnology (22)
- Health Care (11)
- Pharmaceutical (11)
- Medical (9)
- Therapeutics (7) Show 10 more
- Investments by region
-
- United Kingdom (19)
- United States (5)
- Germany (1)
- Peak activity year
- 2003
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Avg. valuation at time of investment
- 154M
- Group Appearance index
- 0.72
- Avg. company exit year
- 13
- Avg. multiplicator
- 10.28
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Arakis Limited | 26 Apr 2002 | Biotechnology, Pharmaceutical | Early Stage Venture | 21M | England, London, United Kingdom |
Neurotech | 16 Nov 2006 | Biotechnology, Medical, Therapeutics | Early Stage Venture | 35M | United States, Rhode Island |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.